Pharmaceuticals : Shots - Health News Pharmaceuticals

Auvi-Q was pulled from the market in 2015 because of quality concerns. The drug's maker says the problems have been solved and that the product will be available in 2017. AP hide caption

toggle caption
AP

WFYI's Jake Harper reports health stories for Side Effects Public Media in Indianapolis. His newest health anxiety stems from the human papillomavirus, or HPV. Brian Paul/Side Effects Public Media hide caption

toggle caption
Brian Paul/Side Effects Public Media

Is 20-Something Too Late For A Guy To Get The HPV Vaccine?

  • Download
  • <iframe src="https://www.npr.org/player/embed/497677367/498219569" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

A job reviewing drug applications at the Food and Drug Administration can be the springboard for a career in industry. Andrew Harnik/AP hide caption

toggle caption
Andrew Harnik/AP

Duchenne muscular dystrophy patients Jack Willis (center), Nolan Willis (right) and Max LeClaire, attended the opening of Sarepta Therapeutics new headquarters in Cambridge, Mass., in 2014. Boston Globe via Getty Images hide caption

toggle caption
Boston Globe via Getty Images

Controversy Continues Over Muscular Dystrophy Drug, Despite FDA Approval

  • Download
  • <iframe src="https://www.npr.org/player/embed/495174472/495295191" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Where are the generic alternatives to EpiPen and other expensive drugs that have lost patent protection? Victor J. Blue/Bloomberg via Getty Images hide caption

toggle caption
Victor J. Blue/Bloomberg via Getty Images

Experimental drugs that clear clumps of proteins from the brains of Alzheimer's patients haven't panned out yet. Science Photo Library/Pasieka/Getty Images hide caption

toggle caption
Science Photo Library/Pasieka/Getty Images

Test Of Experimental Alzheimer's Drug Finds Progress Against Brain Plaques

  • Download
  • <iframe src="https://www.npr.org/player/embed/491941518/492133112" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Mylan, the maker of EpiPen, says it will sell a generic version for $300 for a two-pack, a price that consumer advocates say is still too high. The device is used to treat severe allergic reactions. Daniel Acker/Bloomberg via Getty Images hide caption

toggle caption
Daniel Acker/Bloomberg via Getty Images

Maker Of EpiPen To Sell Generic Version For Half The Price

  • Download
  • <iframe src="https://www.npr.org/player/embed/491797051/491848114" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

In states that made medical marijuana legal, prescriptions for a range of drugs covered by Medicare dropped. Chris Hondros/Getty Images hide caption

toggle caption
Chris Hondros/Getty Images

A single modest meal for a doctor was associated with a higher likelihood he or she would prescribe Crestor, a cholesterol drug, instead of a generic. Daniel Acker/Bloomberg via Getty Images hide caption

toggle caption
Daniel Acker/Bloomberg via Getty Images

A federal judge has agreed to end a trial of FedEx which started Monday in San Francisco. The firm had been accused of shipping packages from illegal online pharmacies. Prosecutors did not specify why they abruptly moved to drop the case. Seth Perlman/AP hide caption

toggle caption
Seth Perlman/AP

This prototype built by MIT researchers can be reconfigured to manufacture different types of pharmaceuticals. Courtesy of the Allan Myerson lab hide caption

toggle caption
Courtesy of the Allan Myerson lab

Inventing A Machine That Spits Out Drugs In A Whole New Way

  • Download
  • <iframe src="https://www.npr.org/player/embed/478576727/479207958" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript